All In Biotech

Drug Trial Radar · NCT07901114

A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult Volunteers

A Randomized, Open-Label, Fasting, 2-Period, 2-Sequence Crossover Study to Evaluate the Bioequivalence and Safety of AJU-C719 and C719R in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
AJU Pharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the bioequivalence and safety of "AJU-C719" and "C719R" in healthy adult subjects.

Conditions

  • Hypertension

Interventions

  • Test DrugDrug

    AJU-C719

  • Reference DrugDrug

    C719R

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCt of AJU-C719Time frame: Pre-dose(0 hours) ~ 72 hours
  2. Cmax of AJU-C719Time frame: Pre-dose(0 hours) ~ 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bumin Hospital (Seoul)

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.